Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:20:09 EDT Mon 06 May 2024
Enter Symbol
or Name
USA
CA



Q:VNDA - VANDA PHARMACE INC - http://www.vandapharma.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
VNDA - Q0.14.95·5.300.84.88+0.204.3677.93,0473,2114.71  4.91  4.70017.00  3.29519:38:06Apr 3015 min RT 2¢

Recent Trades - Last 10 of 3211
Time ETExPriceChangeVolume
19:38:06Q5.00010.320110
19:02:51Q5.030.351,000
18:59:01Q5.010.331,000
18:53:09Q5.020.341,000
18:52:18Q5.01840.338410,000
18:52:02Q5.020.341,000
18:38:06Q4.990.3134
18:10:38Q5.030.35350
18:07:34Q4.970.2915
18:04:14Q4.990.3115

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-30 16:30U:VNDANews ReleaseVanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024
2024-04-25 08:06U:VNDANews ReleaseShareholder Capital Delivers Letter to Independent Members of the Board of Vanda Pharmaceuticals
2024-04-22 19:12U:VNDANews ReleaseVanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ(TM) ANDA Litigation
2024-04-17 10:21U:VNDANews ReleaseVanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan
2024-04-17 09:02U:VNDANews ReleaseVanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak
2024-04-02 18:10U:VNDANews ReleaseVanda Pharmaceuticals' Fanapt(TM) (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder
2024-03-06 07:00U:VNDANews ReleaseVanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ(TM) in the Treatment of Insomnia
2024-02-07 16:02U:VNDANews ReleaseVanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-05 08:00U:VNDANews ReleaseVanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ ‚ ® in the Treatment of Insomnia
2024-01-31 16:30U:VNDANews ReleaseVanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 7, 2024
2024-01-31 09:00U:VNDANews ReleaseVanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of Onychomycosis
2024-01-30 12:35U:VNDANews ReleaseCourt Orders FDA to Resolve Vanda Pharmaceuticals' Jet Lag Hearing Request by March 5, 2024
2024-01-29 19:00U:VNDANews ReleaseCourt Orders FDA to Resolve Vanda Pharmaceuticals' Jet Lag Hearing Request by March 5, 2024
2024-01-25 22:05U:VNDANews ReleaseVanda Pharmaceuticals Announces a U.S. Patent Allowance for PONVORY ‚ ® (ponesimod) in the U.S.
2024-01-25 13:07U:VNDANews ReleaseVanda Pharmaceuticals announces the publication of an article on "The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Clinical Trial" in the Clinical Gastroenterology and Hepatology
2024-01-23 09:15U:VNDANews ReleaseVanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S
2024-01-19 15:56U:VNDANews ReleaseFederal Court Allows Vanda Pharmaceuticals' Lawsuit to Proceed Against the U.S. Food and Drug Administration
2024-01-17 15:46U:VNDANews ReleaseVanda Pharmaceuticals announces the publication of Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study in the Journal of Clinical Psychiatry
2024-01-12 12:21U:VNDANews ReleaseVanda Pharmaceuticals Comments on FDA's Recently Announced Guidance on Communication with Health Care Professionals Regarding FDA-Approved Drugs
2024-01-04 16:30U:VNDANews ReleaseVanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference